Global Market for Lysosomal Disease Treatments to Reach $7.6 Billion by 2023

October 30, 2018

WELLESLEY, Mass., Oct 30, 2018 – Due to increasing awareness, rising focus by pharmaceutical companies, early diagnosis and newborn screening, the global market for lysosomal disease treatments is experiencing continued growth, according to a report from BCC Research.

In 2018, the global market for lysosomal disease treatments was worth $5.1 billion. However, BCC Research estimates that it will reach a value of $7.6 billion by 2023, indicating a compound annual growth rate (CAGR) of 8.3%, according to Lysosomal Disease Treatments: Technologies and Global Markets.

The lysosomal storage diseases (LSDs) are a group of 50 diseases that are characterized by accumulation of waste product in the lysosomes. They are rare inborn defects and have a combined incidence rate of 1 in 1500 to 7000 live births. In lysosomal storage diseases, there is a deficiency of one or more of the many catabolic enzymes that are located within the lysosome.

Research Highlights

  • With 31.3%, Gaucher’s Disease accounted for the largest share of the market for the LSD market in 2018. This disease market is expected to reach nearly $2.2 billion by 2023, at a CAGR of 6.2%.
  • Major companies that are influencing the outcomes of the market include Sanofi (SNY), Pfizer (PFE) and Shire (SHPGF).
  • The market also faces a few restraints that include expensive drugs, change in payer policies, lack of proper training and knowledge, nature of disease and concerns in diagnosis.

“There have been marked advancements in the treatment of LSDs; this has been possible by the improved knowledge of their molecular bases and pathophysiology,” said report author, Neha Maliwal. “Additionally, availability of technologies allowing large-scale production, purification and manipulation of new drugs, recombinant proteins and viral vectors, and as well the orphan drug legislation have given a boost to the development of therapies for LSDs and has encouraged biotech companies to invest in the treatments for rare diseases.”

Editors/reporters requesting analyst interviews should contact Eric Surber at

Lysosomal Disease Treatments: Technologies and Global Markets( PHM183A )
Publish Date: Sep 2018    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email or visit to request access to our library of market research.